Tiny silica particles wiped out aggressive prostate cancer in mice
Scientists have developed silica nanoparticles that can destroy prostate tumors in mice while simultaneously activating the immune system to fight cancer. This dual-action approach shows promise for future human clinical trials as a new paradigm in cancer treatment.
Why it matters
This development represents a potential breakthrough in cancer therapy by combining direct tumor destruction with immune system stimulation.
Researchers have developed tiny silica nanoparticles that can directly destroy prostate tumors while also awakening the body's immune system to fight cancer, according to a new preclinical study led by scientists at Weill Cornell Medicine and the Cornell Duffield College of Engineering. In mouse models of aggressive prostate cancer, the targeted particles produced several complete tumor remissions, offering encouraging evidence that the approach could eventually advance to human clinical trials.
The article reports on preclinical study results in a neutral, scientific manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in